Illustrative image.
Kisunla
Donanemab‑azbt
$15400.00
350mg · 11 × 1 vial · 3 months supply
BrandBranded medicine· By Eli lilly
$5133.33 per month
How long a supply?
Test mode: no payment is taken. View cart
Annual cost
$64400a year at this pack size
Prescription required
Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.
FDA boxed warningAmyloid related imaging abnormalities
Monoclonal antibodies directed against aggregated forms of beta amyloid, including KISUNLA, can cause amyloid related imaging abnormalities (ARIA), characterized as ARIA with edema (ARIA-E) and ARIA with hemosiderin deposition (ARIA-H). Incidence and timing of ARIA vary among treatments. ARIA usually occurs early in treatment and is usually asymptomatic, although serious and life-threatening events can occur. ARIA can be fatal. Serious intracerebral hemorrhages >1 cm, some of which have been fatal, have been observed in patients treated with this class of medications. Because ARIA-E can cause focal neurologic deficits that can mimic an ischemic stroke, treating clinicians should consider whether such symptoms could be due to ARIA-E before giving thrombolytic therapy in a patient being treated with KISUNLA
ApoE ε4 Homozygotes
Consider the benefit of KISUNLA for the treatment of Alzheimer's disease and potential risk of serious adverse events associated with ARIA when deciding to initiate treatment with KISUNLA
Monoclonal antibodies directed against aggregated forms of beta amyloid, including KISUNLA, can cause amyloid related imaging abnormalities (ARIA), as ARIA with edema (ARIA-E) and ARIA with hemosiderin deposition (ARIA-H). ARIA is usually asymptomatic, although serious and life-threatening events can occur. ARIA can be fatal. Serious intracerebral hemorrhages >1 cm have occurred in patients treated with this class of medications. ARIA-E can cause focal neurologic deficits that can mimic ischemic stroke.
ApoE
ε4 Homozygotes
4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA. Prior to testing, the risk of ARIA across genotypes and implications of genetic testing results should be discussed with patients.
Consider the benefit for the treatment of Alzheimer's disease and risk of ARIA when deciding to treat with KISUNLA.
About Kisunla
Overview
Kisunla (donanemab-azbt) is a monoclonal antibody medicine used to treat Alzheimer’s disease. Treatment should begin in people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. It targets amyloid beta and reduces amyloid plaques in the brain.
What it treats
Alzheimer’s disease, with treatment started at the mild cognitive impairment or mild dementia stage.
Safety information
Side effects
Common side effects include headache and amyloid-related imaging abnormalities (ARIA): ARIA-E, microhemorrhages (small bleeds), and superficial siderosis. Serious reactions include ARIA, allergic reactions and infusion-related reactions. Contact your doctor if you suspect any of these reactions. Suspected ARIA requires medical assessment, which may include an MRI scan. Extra vigilance for ARIA is recommended during the first 24 weeks of treatment. Its risk is higher in people with two copies of the ApoE ε4 gene and in those with certain pre-existing MRI findings, including microhemorrhages or superficial siderosis.
FDA boxed warning
Amyloid related imaging abnormalities
Monoclonal antibodies directed against aggregated forms of beta amyloid, including KISUNLA, can cause amyloid related imaging abnormalities (ARIA), characterized as ARIA with edema (ARIA-E) and ARIA with hemosiderin deposition (ARIA-H). Incidence and timing of ARIA vary among treatments. ARIA usually occurs early in treatment and is usually asymptomatic, although serious and life-threatening events can occur. ARIA can be fatal. Serious intracerebral hemorrhages >1 cm, some of which have been fatal, have been observed in patients treated with this class of medications. Because ARIA-E can cause focal neurologic deficits that can mimic an ischemic stroke, treating clinicians should consider whether such symptoms could be due to ARIA-E before giving thrombolytic therapy in a patient being treated with KISUNLA
ApoE ε4 Homozygotes
Consider the benefit of KISUNLA for the treatment of Alzheimer's disease and potential risk of serious adverse events associated with ARIA when deciding to initiate treatment with KISUNLA
Monoclonal antibodies directed against aggregated forms of beta amyloid, including KISUNLA, can cause amyloid related imaging abnormalities (ARIA), as ARIA with edema (ARIA-E) and ARIA with hemosiderin deposition (ARIA-H). ARIA is usually asymptomatic, although serious and life-threatening events can occur. ARIA can be fatal. Serious intracerebral hemorrhages >1 cm have occurred in patients treated with this class of medications. ARIA-E can cause focal neurologic deficits that can mimic ischemic stroke.
ApoE
ε4 Homozygotes
4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA. Prior to testing, the risk of ARIA across genotypes and implications of genetic testing results should be discussed with patients.
Consider the benefit for the treatment of Alzheimer's disease and risk of ARIA when deciding to treat with KISUNLA.
A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.
When to call your doctor
If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.
Before taking this medicine
Kisunla must not be used in anyone with a known serious allergy to donanemab-azbt or any of its other ingredients. Serious allergic reactions, including anaphylaxis, have occurred. Kisunla requires careful monitoring for amyloid-related imaging abnormalities (ARIA), particularly during the first 24 weeks of treatment. The risk, including ARIA with symptoms, is higher in people with two copies of the ApoE ε4 gene than in those with one or no copies. Pre-existing small brain bleeds or superficial siderosis also increase the risk. Symptoms suggesting ARIA require clinical assessment, which may include an MRI scan. Infusion-related reactions may require the infusion to be slowed or stopped and appropriate treatment given. Medicines to help prevent reactions may be considered before later infusions.
Using Kisunla
Dosing
Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.
Storage
Store in the original carton below 25°C, protected from light, unless the pack states refrigeration. Do not freeze. Keep all medicines out of the sight and reach of children.
Clinical information on this page is summarised from the US FDA label KISUNLA (DONANEMAB-AZBT) INJECTION, SOLUTION [ELI LILLY AND COMPANY] (DailyMed, retrieved 19 September 2026).
Reviews
No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.
- Every prescription order is checked by a licensed pharmacist before dispensing.
- Payment pages are encrypted and card details never reach our servers.
- We ship internationally, with cold-chain packing where a medicine needs it.
Related medicines
Aricept
Donepezil
Tablets · from 28 per pack
Also for alzheimers
Brand and generic from $55.00
Exelon
Rivastigmine
By Novartis
Capsules and Patch · from 28 per pack
Also for alzheimers
Brand from $44.00
Razadyne
Galantamine Hbr
By Janssen Cilag
Capsules · from 28 per pack
Also for alzheimers
Brand from $92.00
Leqembi
Lecanemab
By Eisai
Vial · from 1 per pack
Also for alzheimers
Brand from $550.00